For almost a decade, BioCentury and BayHelix and our partners have brought together a global community of C-suite executives and investors focused on biopharma innovation and cross-border collaboration. But the world has changed: Emerging biopharmas in the U.S., Europe and Asia now face the same dilemma: How do you globalize to deliver innovation to patients and achieve an ROI for investors?

• A handful of biopharma companies will build global operations.
• Most will achieve global economics through partnering and licensing.
• Others will capture a share of the economics by enabling global development and financing.
• And all will require trusted cross-border relationships for success.

Globalizing drug development is imperative for creating medicines that reach all patients, regardless of where they live. That takes investors and company leaders with global vision and strategy, in a rapidly evolving environment.

Hear from:

• David Reese, M.D., EVP of R&D, Amgen
• John Lepore, SVP & Head of Research, GlaxoSmithKline
• Kiran Reddy, Senior Managing Director, Blackstone
• Chris Carpenter, M.D., Ph.D., Executive Partner, Sofinnova Investments

And many more….

*Digital passes also available.